<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03777085</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2303-III-01</org_study_id>
    <nct_id>NCT03777085</nct_id>
  </id_info>
  <brief_title>Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and&#xD;
      Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously&#xD;
      Untreated Patients with Diffuse Large B-cell Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (CR+CRu)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>:Overall survival (OS)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>TQB2303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2303</intervention_name>
    <description>375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks</description>
    <arm_group_label>TQB2303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Untreated CD20-positive DLBCL patients confirmed by histopathology or cytology.&#xD;
&#xD;
          2. 18 years to 75 years; Male or female patients.&#xD;
&#xD;
          3. International Prognostic Index (IPI) score of 0 to 2.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          5. More than 6 months life expectancy judged by the researchers.&#xD;
&#xD;
          6. At least one measurable lesions: for nodal tumor mass, more than 1.5 cm in the long&#xD;
             axis and more than 1.0 cm in the short axis; for extranodal tumor mass, more than 1.0&#xD;
             cm in the long axis.&#xD;
&#xD;
          7. left ventricular ejection fraction (LVEF) measured by the Cardiac echocardiography&#xD;
             greater than or equal to 50%.&#xD;
&#xD;
          8. Adequate hematologic function, no matter the bone marrow was attacked or not, as&#xD;
             follows:absolute neutrophil count (ANC) ≥1.5×10^9/L and platelet count≥75×^9/L.&#xD;
&#xD;
          9. Understood and Signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergic reactions against human or murine monoclonal antibody, murine products,&#xD;
             or foreign proteins.&#xD;
&#xD;
          2. Known allergic reactions against any component of CHOP regimen.&#xD;
&#xD;
          3. Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial&#xD;
             radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and&#xD;
             surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody&#xD;
             within 3 month.&#xD;
&#xD;
          4. T-cell/histiocyte-rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary&#xD;
             cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly (EBV + DLBCL),&#xD;
             EBV-positive DLBCL of the elderly (EBV + DLBCL), DLBCL associated with chronic&#xD;
             infammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell&#xD;
             lymphoma (PMBL), ALK-positive large B-cell lymphoma, ALK-positive large B-cell&#xD;
             lymphoma, ALK-positive large B-cell lymphoma, high-grade B-cell lymphoma (high-grade&#xD;
             B-cell lymphoma with MYC, with or without concurrent in BCL2 and/or BCL6 gene&#xD;
             rearrangements, high-grade B-cell lymphoma, NOS), B-cell lymphoma, Not categorizable,&#xD;
             Characteristics between DLBCL and classical Hodgkin's lymphoma, transformed DLBCL,&#xD;
             DLBCL secondary central nervous system invasion;&#xD;
&#xD;
          5. Other malignant tumors that have been or are currently suffering (healed skin basal&#xD;
             cell carcinoma or cutaneous squamous cell carcinoma, or cutaneous melanoma or cervical&#xD;
             carcinoma in situ).&#xD;
&#xD;
          6. Significantly poorly controlled diseases that can affect adherence to the study&#xD;
             protocol, such as severe cardiovascular disease (such as the New York Heart&#xD;
             Association class III or IV heart disease, myocardial infarction or unstable&#xD;
             arrhythmia in the last 6 months or Unstable angina, severe hypertension, peripheral&#xD;
             nervous system or central nervous system disease;&#xD;
&#xD;
          7. Patients with a history of progressive multifocal leukoencephalopathy.&#xD;
&#xD;
          8. Continuous corticosteroid treatment being received, dose &gt;30 mg/day prednisone or&#xD;
             equivalent dose of corticosteroids ≥10 days.&#xD;
&#xD;
          9. Participation in another interventional clinical trial in the past 3 months.&#xD;
&#xD;
         10. Patients who received or underwent major surgeries within 28 days prior to enrollment,&#xD;
             or patients with unsurgical wounds.&#xD;
&#xD;
         11. Treated with transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor&#xD;
             (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days&#xD;
             prior to enrollment.&#xD;
&#xD;
         12. Vaccination within 28 days or planned prior to enrollment.&#xD;
&#xD;
         13. Appearing the following laboratory abnormal values.&#xD;
&#xD;
               1. Coagulation function: partial prothrombin time (PTT) or activated partial&#xD;
                  thromboplastin time (aPTT) or international normalized ratio (INR) &gt; 1.5 times&#xD;
                  ULN without anticoagulant therapy.&#xD;
&#xD;
               2. Liver function: total bilirubin (TBIL) &gt; 1.5 times the upper limit of normal (3&#xD;
                  times the upper limit of normal value when the liver is invaded), alanine&#xD;
                  aminotransferase (ALT) and / or aspartate aminotransferase (AST) &gt; 2.5 times the&#xD;
                  upper limit of normal value (&gt;5 times the upper limit of normal value when the&#xD;
                  liver is invaded)&#xD;
&#xD;
               3. Renal function: serum creatinine (Cr) &gt; 1.5 times the upper limit of normal&#xD;
                  value.&#xD;
&#xD;
         14. an active infection at the time of enrollment, or any major infection events that&#xD;
             affected the enrollment of the subjects determined by the investigator within 28 days&#xD;
             (except for neoplastic fever).&#xD;
&#xD;
         15. Suspected active or latent tuberculosis infections.&#xD;
&#xD;
         16. HBsAg positive and/or HBcAb positive and HBV DNA positive.&#xD;
&#xD;
         17. HCV antibody and HCV-RNA positive; or HIV positive patients.&#xD;
&#xD;
         18. Pregnancy or breast feeding. Companion for women of childbearing age or women of&#xD;
             childbearing age,who reluctant to take appropriate contraceptive methods within one&#xD;
             year after the last treatment of the study;Pregnancy before pregnancy screening, the&#xD;
             women who blood / urine results were positive.&#xD;
&#xD;
         19. Patients that researchers deem as not appropriate to enter the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>No.150 Haping Road, Nangang District</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, Doctor</last_name>
      <phone>0451-86298681</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 42 Baiziting Road, Xuanwu District</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng Feng, doctor</last_name>
      <phone>025-83284615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.8 Jiangtan Road,Weibin District</name>
      <address>
        <city>Baoji</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazhou Yao, Doctor</last_name>
      <phone>0917-3390942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 87 Xiangya Road Furong District</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xielan Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.138 Tongzipo Road Yuelu District</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiguo Cao</last_name>
      <phone>0731-88618285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.139 Renmin Middle Road Furong District</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunhong Hu</last_name>
      <phone>0731-85295929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 37 Guoxue Lane Wuhou District</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuping Gong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 55 Section 4 Renmin South Road Wuhou District</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihui Zhang</last_name>
      <phone>028-85420057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 10 Daping Yangtze River Branch Road Yuzhong District</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wang</last_name>
      <phone>023-68757150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.183 Xinqiao Main Street Shapingba District</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Liu</last_name>
      <phone>023-68774309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.420 Fuma Road, Jin'an district</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Yang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.295 Xichang Road, Wuhua District</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zeng</last_name>
      <phone>0871-65324888-2522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 701 Donggang Road (West) Chengguan District</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Xi</last_name>
      <phone>0931-8356912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 82 Cuiyingmen Chengguan District</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chongyang Wu</last_name>
      <phone>0931-8943196</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.333 Nanbinhe Middle Road Qilihe District</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai Bai</last_name>
      <phone>0931-8995099</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 8 Wenchang Road Chengzhong District</name>
      <address>
        <city>Liuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinxiong Huang</last_name>
      <phone>0772-2662805</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.519 Beijing East Road High - tech District</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuerong Shuang</last_name>
      <phone>0791-88329441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.71 Embankment Road, Qingxiu District</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Cen, Doctor</last_name>
      <phone>0771-5390813</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.20 Xisi Road Chongchuan District</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Liu</last_name>
      <phone>0513-81160502</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.1677 Wutai Mountain Road Huangdao District</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongwei Xue</last_name>
      <phone>0532-82919699</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 151 Guangwen Street Kuiwen District</name>
      <address>
        <city>Weifang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuehong Ran</last_name>
      <phone>0536-8192116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 3, West Mt. East Road, Wendeng District, Weihai City</name>
      <address>
        <city>Weihai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghua Wang</last_name>
      <phone>0631-3793349</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 1277 Jiefang Avenue Jianghan District</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liling Zhang</last_name>
      <phone>0278-5872257</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No 137 Carp mountain Road New district</name>
      <address>
        <city>Wulumuqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinhong Guo</last_name>
      <phone>0991-4361350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.31 Hygienic Lane Haizang Road Liangzhou District</name>
      <address>
        <city>Wuwei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youquan Dang, Doctor</last_name>
      <phone>0935-2268046</phone>
    </contact>
    <investigator>
      <last_name>Cong Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No. 15 West ChangLe Road New City District</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangxun Gao</last_name>
      <phone>029-84775202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.256 Youyi West Road Beilin District</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 7 Weiwu Road Jinshui District</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zunmin Zhu</last_name>
      <phone>0371-65896920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.1 Jianshe East Road Erqi District</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.127 Dongming Road, Jinshuii District</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yufu Li, Doctor</last_name>
      <phone>0371-65587306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 54 Communist Youth League Road Zhangdian District</name>
      <address>
        <city>Zibo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhencheng Wang</last_name>
      <phone>0533-2360985</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03777085
org study id: TQB2303-III-01
nct id: NCT03777085
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and
      Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously
      Untreated Patients with Diffuse Large B-cell Lymphoma
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Investigator)
measure: Overall response rate (ORR)
time frame: 18 weeks
measure: Objective Response Rate (CR+CRu)
time frame: 18 weeks
measure: Progression-free survival (PFS)
time frame: 18 weeks
measure: Event-free survival (EFS)
time frame: 18 weeks
measure: Duration of Response (DOR)
time frame: 18 weeks
measure: :Overall survival (OS)
time frame: 18 weeks
arm group label: TQB2303
arm group type: Experimental
arm group label: Rituximab
arm group type: Active Comparator
intervention type: Drug
intervention name: TQB2303
description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
arm group label: TQB2303
intervention type: Drug
intervention name: Rituximab
description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
arm group label: Rituximab
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: China
responsible party type: Sponsor
mesh term: Lymphoma
mesh term: Lymphoma, B-Cell
mesh term: Lymphoma, Large B-Cell, Diffuse
mesh term: Rituximab